Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

ErratumIn

Leukemia. 2025 Mar 30. doi: 10.1038/s41375-025-02597-4.

COI Statement

Competing interests: PJB is and advisor or consultant for Hexal, Merck Sharp & Dohme, Need Inc., Stemline and Takeda; holds stock options in Need Inc., has received honoraria from AstraZeneca, BeiGene, BMS/Celgene, Lilly, Merck Sharp & Dohme, Need Inc., Stemline and Takeda and reports research funding from BeiGene (Inst), BMS (Inst), Merck Sharp & Dohme (Inst) and Takeda (Inst); MF reports honoraria from BMS/Celgene, Janssen and Takeda and he is the CEO of KARO GmbH; DAE reports honoraria from Takeda and Sanofi-Genzyme; SB reports a consultant role for Galapagos, has received honoraria from Takeda, reports travel support from Takeda and reports being founder and shareholder of Liqomics; JF reports and advisory role for Takeda Oncology and speaker fees from Roche Pharma and Takeda Oncology; BB has received honoraria and research funding from Amgen, Gilead, MSD, Miltenyi, Noscendo, Novartis, Pfizer and Takeda; WK reports research grants by Roche, Amgen, Takeda, Janssen and InCyte, all to the institution; BvT is an advisor or consultant for Allogene, Amgen, BMS/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, Sobi, Serb and Takeda; has received honoraria from AbbVie, AstraZeneca, BMS/Celgene, Gilead Kite, Incyte, Lilly, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Roche and Takeda; reports research funding from Esteve (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, Gilead Kite, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, and Novartis; is member of steering committees for Regeneron and Takeda. All other authors don’t declare any potential conflicts of interest.

References:

• Guideline on the clinical evaluation of anticancer medicinal products - Revision 6. European Medicines Agency; 2024.
• Brockelmann PJ, McMullen S, Wilson JB, Mueller K, Goring S, Stamatoullas A, et al. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol. 2019;184:202–14.
• Bröckelmann PJ, Müller H, Fuchs M, Gillessen S, Eichenauer DA, Borchmann S, et al. Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials. Ann Oncol. 2024;S0923-7534:04988-3. https://doi.org/10.1016/j.annonc.2024.12.009 . Online ahead of print.
• Brockelmann PJ, Muller H, Gillessen S, Yang X, Koeppel L, Pilz V, et al. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia. 2022;36:772–80.
• Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, et al. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. 2023;141:2727–37.